<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00426153</url>
  </required_header>
  <id_info>
    <org_study_id>06-004128</org_study_id>
    <secondary_id>UL1RR024150</secondary_id>
    <nct_id>NCT00426153</nct_id>
  </id_info>
  <brief_title>Octreotide in Severe Polycystic Liver Disease</brief_title>
  <official_title>Pilot Study Of Long-Acting Octreotide (Octreotide LAR® Depot) In The Treatment Of Patients With Severe Polycystic Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of Octreotide LAR® on the liver volumes of patients with
      severe polycystic liver disease who are not candidates or decline surgical treatments such as
      liver cyst fenestration, liver resection or liver transplantation. A total of 42 patients
      will be recruited -14 who will receive placebo and 28 the study drug. Preliminary evidence
      indicates that this drug is safe and non-toxic in other disease states. Treatment with this
      drug holds promise not only for individuals with liver involvement, but also for many more
      patients with polycystic kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of this study is to compare the effect of Octreotide LAR® Depot on the liver
      volume of patients with severe polycystic liver disease who are not candidates or decline
      surgical treatments such as liver cyst fenestration, liver resection or liver transplantation
      compared with placebo. The secondary aims of the study are: (1)Assess the effect of
      Octreotide LAR® Depot on the total kidney volume and iothalamate clearance in patients with
      polycystic kidney disease associated with severe polycystic liver disease who are not
      candidates or decline surgical treatments such as liver cyst fenestration, liver resection or
      liver transplantation. (2)Evaluate quality of life changes associated with the administration
      of Octreotide LAR® Depot in these patients. (3)Assess toxicity of Octreotide LAR® Depot in
      patients with polycystic liver disease (PLD).

      Note: Subjects who completed this 1 year randomized trial were offered enrollment into an
      open-label (all subjects received Octreotide) extension trial for an additional two years of
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Liver Volume</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Percent change from baseline in liver volume, measured in milliliters by Magnetic Resonance Imaging (MRI)or Computed Tomography (CT) scans</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Renal Volume</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Percent change from baseline in renal volume, measured in milliliters by MRI or CT scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Glomerular Filtration Rate (GFR)</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Percent change from baseline in renal function/GFR, measured by clearance of iothalamate with monitoring of bladder emptying using ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Subject Reported Outcomes Using Mean Health Related Quality of Life (HRQoL) Scores</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Scores on the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36), version 2. Subjects completed the SF-36 which consists of 8 sub-scales which are additionally summarized into 2 summary components (physical and mental). The subscales and the summary scales both range from 0 to 100, with (0 = worst imaginable, 100 = best imaginable).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Polycystic Kidney, Autosomal Dominant</condition>
  <condition>Polycystic Liver Disease</condition>
  <condition>Hepatomegaly</condition>
  <condition>Liver Diseases</condition>
  <condition>Kidney, Polycystic</condition>
  <condition>Abdominal Pain</condition>
  <arm_group>
    <arm_group_label>Octreotide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received Octreotide LAR® Depot injections (up to 40 mg) intramuscularly every 28 days (+/- 5 days) for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide</intervention_name>
    <description>Participants received Octreotide LAR® Depot injections (up to 40 mg)intramuscularly every 28 days (+/- 5 days) for one year</description>
    <arm_group_label>Octreotide</arm_group_label>
    <other_name>Octreotide LAR® Depot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age - 18 years and older

          -  Diagnosis of Polycystic Liver Disease (PLD) associated with ADPKD or isolated
             Autosomal Dominant Polycystic liver Disease (ADPLD)

          -  Severe PLD defined as a liver volume greater than 4000 mL or symptomatic disease due
             to mass effects from hepatic cysts

          -  Not a candidate for or declining surgical intervention

        Exclusion Criteria:

          -  Women of childbearing potential or their sexual partners who are unwilling to employ
             adequate contraception

          -  Creatinine greater than 3mg/dL or hemodialysis dependent

          -  Cancer or major systemic disease that could prevent completion of the planned
             follow-up or interfere with data collection or interpretation

          -  Uncontrolled diabetes mellitus as defined by blood glucose levels of greater than or
             equal to 250 mg/dL on 2 or more consecutive daily readings despite antidiabetic
             therapy

          -  Neurologic/psychologic conditions preventing appropriate informed consent

          -  Symptomatic gallstones or biliary sludge

          -  Variceal bleeding or hepatic encephalopathy within prior 30 days

          -  Uncontrolled hypertension (Systolic blood pressure greater than 160 mmHg; Diastolic
             blood pressure greater than 100 mmHg)

          -  Current, or prior use of somatostatin analogue (octreotide, lanreotide) in past 6
             months

          -  History of significant adverse reaction to a somatostatin analogue
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie C. Hogan, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <results_reference>
    <citation>Hogan MC, Masyuk TV, Page L, Holmes DR 3rd, Li X, Bergstralh EJ, Irazabal MV, Kim B, King BF, Glockner JF, Larusso NF, Torres VE. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant. 2012 Sep;27(9):3532-9. doi: 10.1093/ndt/gfs152. Epub 2012 Jul 6.</citation>
    <PMID>22773240</PMID>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2007</study_first_submitted>
  <study_first_submitted_qc>January 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2007</study_first_posted>
  <results_first_submitted>October 22, 2012</results_first_submitted>
  <results_first_submitted_qc>October 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 21, 2012</results_first_posted>
  <last_update_submitted>October 22, 2012</last_update_submitted>
  <last_update_submitted_qc>October 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Marie Hogan</investigator_full_name>
    <investigator_title>MD, PhD, Assistant Professor of Medicine, College of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Abdominal Pain</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Cysts</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
    <mesh_term>Hepatomegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>42 participants were enrolled at Mayo Clinic in Rochester, Minnesota from 1/1/2007 to 5/19/2008.</recruitment_details>
      <pre_assignment_details>Following consent a tolerability test dose of 100 micrograms of short-acting octreotide was administered subcutaneously to subjects, followed by 4 hours of observation/vital signs. Randomized intramuscular dosing began the next day.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Octreotide</title>
          <description>Participants received Octreotide LAR® Depot injections intramuscularly every 28 days (+/- 5 days) for one year</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28">Participants were randomized in a 2:1 ratio, Octreotide LAR depot: Placebo</participants>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Octreotide</title>
          <description>Participants received Octreotide LAR® Depot injections intramuscularly every 28 days (+/- 5 days) for one year</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.7" spread="9"/>
                    <measurement group_id="B2" value="50.3" spread="7.3"/>
                    <measurement group_id="B3" value="49.9" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glomerular Filtration Rate</title>
          <description>Glomerular Filtration Rate measures how fast the kidneys are filtering. 13 subjects were excluded from the analysis of the kidney data: 4 subjects had renal transplant before enrollment (3 in octreotide and 1 in placebo groups), 8 subjects had a diagnosis of ADPLD (4 in each group), 1 placebo subject has missing kidney data due to incomplete image coverage.</description>
          <units>milliliters/minute per 1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" spread="27"/>
                    <measurement group_id="B2" value="71" spread="27"/>
                    <measurement group_id="B3" value="70" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>Body Mass Index (BMI) is a health index for comparing weight to height. BMI is a person's weight in kilograms (kg) divided by his or her height in meters squared. The body mass index is an indication if a person is at a suitable weight for his height on an approximation of body fat. A body mass index of under 20 is considered to be underweight, while a body mass index between 20 to 25 is considered healthy. A body mass index in the range of 25 to 30 is regarded as overweight. A body mass index over 30 is regarded as obese.</description>
          <units>kilograms/meter^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.3" spread="5.77"/>
                    <measurement group_id="B2" value="24.4" spread="2.98"/>
                    <measurement group_id="B3" value="25.7" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.0" spread="20.2"/>
                    <measurement group_id="B2" value="70.9" spread="10.9"/>
                    <measurement group_id="B3" value="74.3" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum creatinine</title>
          <description>Creatinine in the serum is a blood test, and is an indicator of kidney function.</description>
          <units>milligrams/deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.1" spread="0.4"/>
                    <measurement group_id="B2" value="1.1" spread="0.5"/>
                    <measurement group_id="B3" value="1.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting plasma glucose</title>
          <units>milligrams/deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93.4" spread="11.2"/>
                    <measurement group_id="B2" value="93.6" spread="7.8"/>
                    <measurement group_id="B3" value="93.5" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine Albumin</title>
          <description>A protein urine test measures the amount of proteins, such as albumin, found in a urine sample. Urine albumin is an indicator of kidney function.</description>
          <units>milligrams/24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="123"/>
                    <measurement group_id="B2" value="130" spread="237"/>
                    <measurement group_id="B3" value="87" spread="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>Systolic blood pressure is the upper number on a blood pressure reading and measures contraction of the ventricles, or lower chambers of the heart</description>
          <units>millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122.1" spread="13.2"/>
                    <measurement group_id="B2" value="120.5" spread="13.5"/>
                    <measurement group_id="B3" value="121.6" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <description>Diastolic blood pressure is the lower number on a blood pressure reading and measures dilation of the ventricles, or lower chambers of the heart.</description>
          <units>millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.8" spread="8.9"/>
                    <measurement group_id="B2" value="79.1" spread="9.2"/>
                    <measurement group_id="B3" value="79.6" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liver volume</title>
          <description>Liver volume was measured by magnetic resonance imaging (MRI) or computed tomography [CT].</description>
          <units>milliliters (ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5907.7" spread="2915.0"/>
                    <measurement group_id="B2" value="5373.9" spread="3565.4"/>
                    <measurement group_id="B3" value="5729.8" spread="3113.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Kidney volume</title>
          <description>Kidney volume was measured by magnetic resonance imaging (MRI) or computed tomography [CT].
13 subjects were excluded from the analysis of the kidney data: 4 subjects had renal transplant before enrollment (3 in octreotide and 1 in placebo groups), 8 subjects had a diagnosis of ADPLD (4 in each group), 1 placebo subject has missing kidney data due to incomplete image coverage. (Octreotide group n = 21 and placebo group n = 8).</description>
          <units>milliliters (ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1142.9" spread="826.9"/>
                    <measurement group_id="B2" value="803.0" spread="269.1"/>
                    <measurement group_id="B3" value="1049.2" spread="728.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Genotypes and genetic mutations</title>
          <description>Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in one of two genes: PKD1 or PKD2, and is characterized by the development of kidney cysts and other manifestations, of which polycystic live disease (PLD) is most common. Autosomal dominant PLD (ADPLD) also exists as a genetically distinct disease with few or absent kidney cysts. Like ADPKD, ADPLD is genetically heterogeneous, with the 1st two genes identified (PRKCSH &amp; SEC63) accounting for approximately 1/3 to 1/2 of isolated ADPLD cases.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ADPKD genotype with PKD1 gene mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADPKD genotype with PKD2 gene mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADPKD genotype with no genetic mutation detected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADPLD genotype with PRKCSH gene mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADPLD genotype with SEC63 gene mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADPLD genotype with no genetic mutation detected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Liver Volume</title>
        <description>Percent change from baseline in liver volume, measured in milliliters by Magnetic Resonance Imaging (MRI)or Computed Tomography (CT) scans</description>
        <time_frame>Baseline, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Octreotide</title>
            <description>Participants received Octreotide LAR® Depot injections intramuscularly every 28 days (+/- 5 days) for one year</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Liver Volume</title>
          <description>Percent change from baseline in liver volume, measured in milliliters by Magnetic Resonance Imaging (MRI)or Computed Tomography (CT) scans</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="6.77"/>
                    <measurement group_id="O2" value="0.9" spread="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P values &lt;0.05 were considered statistically significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>Rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Renal Volume</title>
        <description>Percent change from baseline in renal volume, measured in milliliters by MRI or CT scans</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>13 subjects were excluded from the analysis of the kidney data: 4 subjects had renal transplant before enrollment (3 in octreotide and 1 in placebo groups), 8 subjects had a diagnosis of ADPLD (4 in each group), 1 placebo subject has missing kidney data due to incomplete image coverage.</population>
        <group_list>
          <group group_id="O1">
            <title>Octreotide</title>
            <description>Participants received Octreotide LAR® Depot injections intramuscularly every 28 days (+/- 5 days) for one year</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Renal Volume</title>
          <description>Percent change from baseline in renal volume, measured in milliliters by MRI or CT scans</description>
          <population>13 subjects were excluded from the analysis of the kidney data: 4 subjects had renal transplant before enrollment (3 in octreotide and 1 in placebo groups), 8 subjects had a diagnosis of ADPLD (4 in each group), 1 placebo subject has missing kidney data due to incomplete image coverage.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="7.53"/>
                    <measurement group_id="O2" value="8.61" spread="10.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.045</p_value>
            <p_value_desc>P values &lt; 0.05 were considered statistically significant</p_value_desc>
            <method>Rank sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Glomerular Filtration Rate (GFR)</title>
        <description>Percent change from baseline in renal function/GFR, measured by clearance of iothalamate with monitoring of bladder emptying using ultrasound</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>13 subjects were excluded from the analysis of the kidney data: 4 subjects had renal transplant before enrollment (3 in octreotide and 1 in placebo groups), 8 subjects had a diagnosis of ADPLD (4 in each group), 1 placebo subject has missing kidney data due to incomplete image coverage.</population>
        <group_list>
          <group group_id="O1">
            <title>Octreotide</title>
            <description>Participants received Octreotide LAR® Depot injections intramuscularly every 28 days (+/- 5 days) for one year</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Glomerular Filtration Rate (GFR)</title>
          <description>Percent change from baseline in renal function/GFR, measured by clearance of iothalamate with monitoring of bladder emptying using ultrasound</description>
          <population>13 subjects were excluded from the analysis of the kidney data: 4 subjects had renal transplant before enrollment (3 in octreotide and 1 in placebo groups), 8 subjects had a diagnosis of ADPLD (4 in each group), 1 placebo subject has missing kidney data due to incomplete image coverage.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="15.46"/>
                    <measurement group_id="O2" value="-7.2" spread="13.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.98</p_value>
            <p_value_desc>P Values &lt; 0.05 were considered statistically significant</p_value_desc>
            <method>Rank sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Subject Reported Outcomes Using Mean Health Related Quality of Life (HRQoL) Scores</title>
        <description>Scores on the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36), version 2. Subjects completed the SF-36 which consists of 8 sub-scales which are additionally summarized into 2 summary components (physical and mental). The subscales and the summary scales both range from 0 to 100, with (0 = worst imaginable, 100 = best imaginable).</description>
        <time_frame>Baseline, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Octreotide</title>
            <description>Participants received Octreotide LAR® Depot injections intramuscularly every 28 days (+/- 5 days) for one year</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Subject Reported Outcomes Using Mean Health Related Quality of Life (HRQoL) Scores</title>
          <description>Scores on the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36), version 2. Subjects completed the SF-36 which consists of 8 sub-scales which are additionally summarized into 2 summary components (physical and mental). The subscales and the summary scales both range from 0 to 100, with (0 = worst imaginable, 100 = best imaginable).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical functioning at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.8" spread="21.96"/>
                    <measurement group_id="O2" value="80.4" spread="23.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical functioning at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0" spread="21.32"/>
                    <measurement group_id="O2" value="82.1" spread="18.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical role at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8" spread="42.13"/>
                    <measurement group_id="O2" value="76.8" spread="39.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical role at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.1" spread="35.00"/>
                    <measurement group_id="O2" value="75.0" spread="41.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.8" spread="15.29"/>
                    <measurement group_id="O2" value="65.5" spread="24.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.7" spread="19.02"/>
                    <measurement group_id="O2" value="68.7" spread="25.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.9" spread="21.29"/>
                    <measurement group_id="O2" value="58.0" spread="23.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.5" spread="17.32"/>
                    <measurement group_id="O2" value="63.4" spread="23.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.6" spread="21.81"/>
                    <measurement group_id="O2" value="53.9" spread="25.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.4" spread="24.23"/>
                    <measurement group_id="O2" value="54.6" spread="27.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.0" spread="19.56"/>
                    <measurement group_id="O2" value="75.0" spread="27.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.9" spread="19.35"/>
                    <measurement group_id="O2" value="81.3" spread="21.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional role at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.1" spread="32.05"/>
                    <measurement group_id="O2" value="73.8" spread="37.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional role at 12 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4" spread="23.74"/>
                    <measurement group_id="O2" value="81.0" spread="38.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental health at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0" spread="14.12"/>
                    <measurement group_id="O2" value="75.4" spread="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental health at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" spread="16.54"/>
                    <measurement group_id="O2" value="80.7" spread="18.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standardized physical component at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6" spread="9.73"/>
                    <measurement group_id="O2" value="46.0" spread="10.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standardized physical component at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" spread="10.00"/>
                    <measurement group_id="O2" value="46.1" spread="9.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standardized mental component at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" spread="7.74"/>
                    <measurement group_id="O2" value="48.4" spread="10.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standardized mental component at 12 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2" spread="8.03"/>
                    <measurement group_id="O2" value="51.3" spread="11.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Octreotide</title>
          <description>Participants received Octreotide LAR® Depot injections intramuscularly every 28 days (+/- 5 days) for one year</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia, incarcerated</sub_title>
                <description>Hernia surgically repaired</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bacteremia</sub_title>
                <description>Bacteremia associated with nephrolithiasis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>UTI, abdominal pain and fever responded to antibiotic therapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea, Grade 1</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Steatorrhea &amp; weight loss</sub_title>
                <description>Subject withdrew from study due to steatorrhea &amp; weight loss</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>abdominal cramping, bloating and gas</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia, moderate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injection site granuloma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marie Hogan, MD, PhD, Assistant Prof of Medicine, College of Medicine</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-9364</phone>
      <email>hogan.marie@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

